What are the hemodynamic assessment criteria and treatment options for ventricular septal defect (VSD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

VSD Hemodynamics and Treatment

Close a VSD when Qp:Qs ≥2.0 with LV volume overload, or when Qp:Qs ≥1.5 with PA pressure <50% systemic and PVR <1/3 systemic; never close when PA pressure >2/3 systemic or with net right-to-left shunt. 1, 2

Hemodynamic Assessment Criteria

Key Parameters to Measure

Echocardiography-Doppler is your primary diagnostic tool 1. You must assess:

  • Shunt magnitude: Calculate Qp:Qs ratio (pulmonary-to-systemic blood flow)
  • Chamber dimensions: Look for LV and left atrial enlargement indicating volume overload
  • Ventricular function: Both LV and RV systolic/diastolic performance
  • Pulmonary artery pressure: Estimate from TR jet velocity, VSD jet, and septal configuration
  • Defect characteristics: Number, location (perimembranous, muscular, supracristal, inlet), and size
  • Associated lesions: Aortic valve prolapse/regurgitation, RV or LV outflow obstruction 1

Hemodynamic Significance Classification

Small VSDs: Qp:Qs <1.5, normal PA pressure, no LV volume overload - these typically require observation only 2

Moderate-to-Large VSDs: Qp:Qs ≥1.5, evidence of LV volume overload, variable PA pressures - these require intervention consideration 3

Eisenmenger Physiology: PA pressure at systemic levels, net right-to-left shunt, cyanosis - closure is contraindicated 1, 2

When to Perform Cardiac Catheterization

Mandatory catheterization when VSD with pulmonary arterial hypertension (PAH) exists to assess operability - this must be done at an ACHD regional center 1

Use catheterization when noninvasive data are inconclusive and you need definitive hemodynamic measurements for management decisions 1

Treatment Algorithm

Class I Indications for Closure (You MUST close)

  1. Qp:Qs ≥2.0 with clinical LV volume overload 1, 4
  2. History of infective endocarditis 1
  3. Qp:Qs ≥1.5 with PA systolic pressure <50% systemic AND PVR <1/3 systemic 2, 4

Class IIa Indications (Closure is Reasonable)

  1. Qp:Qs >1.5 with PA pressure <2/3 systemic AND PVR <2/3 systemic 1
  2. Qp:Qs >1.5 with LV systolic or diastolic failure 1
  3. Worsening aortic regurgitation from perimembranous or supracristal VSD - particularly when aortic valve cusp prolapse is progressive 2, 4

Class IIb Indications (May Consider)

Qp:Qs ≥1.5 when PA pressure is 50-67% systemic and/or PVR is 1/3 to 2/3 systemic - these patients require vasoreactivity testing and expert consultation 2, 3

Class III (DO NOT Close - Contraindicated)

Never close when 1, 2:

  • PA systolic pressure >2/3 systemic
  • PVR >2/3 systemic vascular resistance
  • Net right-to-left shunt present (Eisenmenger syndrome)

The 2019 AHA/ACC guidelines emphasize that 25-year survival for small VSDs is 96%, but drops to 42% with Eisenmenger syndrome 2. Attempting closure in severe irreversible PAH carries prohibitively high mortality 3.

Critical Diagnostic Pitfalls to Avoid

  • Don't mistake VSD jet for TR jet - this leads to false assumption of PAH when pressures are actually normal 1
  • Watch for double-chambered RV or subaortic stenosis developing in patients with known small VSDs - the murmur may not change appreciably 1
  • Monitor for progressive AR in small VSDs with aortic valve prolapse (occurs in 6% of supracristal/perimembranous defects) 2
  • Recognize unrecognized RV outflow obstruction - high-velocity TR jet may falsely suggest PAH 1

Surgical Approach

Surgeons with CHD training and expertise must perform VSD closures 1. The standard approach uses patch closure with synthetic material (Dacron or Gore-Tex) 1. Intraoperative TEE is mandatory to identify additional muscular VSDs that may only manifest after closing the dominant defect 1.

Transcatheter device closure is feasible for muscular VSDs with good safety profile, but perimembranous VSD device closure carries significant complete heart block risk and is not recommended 2, 5.

Post-Intervention Follow-Up

Annual follow-up at ACHD center if residual heart failure, shunts, PAH, AR, or outflow obstruction exists 1

Every 3-5 years for small residual VSD without other lesions 1

Every 1-2 years after device closure depending on VSD location 1

Monitor for late complete heart block development in patients with bifascicular or transient trifascicular block post-closure - yearly ECG and periodic ambulatory monitoring required 1

References

5
Research

Diagnosis and Management of Ventricular Septal Defects.

Reviews in cardiovascular medicine, 2024

Related Questions

How should a small restrictive ventricular septal defect be managed in an asymptomatic 7‑year‑old child?
How should a ventricular septal defect identified on echocardiography be evaluated and managed?
How do I determine the size of a ventricular septal defect?
What are the recommendations for pregnancy in a woman with a ventricular septal defect (VSD), including pre‑conception evaluation, cardiac monitoring during gestation, and delivery management?
What is the significance of the Doppler gradient on echocardiography for a ventricular septal defect and how should it guide management?
What are the recommended treatment options for fungal pneumonia in adults?
What imaging and laboratory studies should be ordered for a patient who fell and hit their head?
What are the recommended directions for using a weight‑based correctional insulin sliding scale in an adult patient (approximately 70 kg) with finger‑stick glucose ≥100 mg/dL?
Can low thiamine (vitamin B1) deficiency cause a false‑positive elevation of amyloid‑related phosphorylated tau 217 (pTau217) measured in a blood biomarker for Alzheimer’s disease?
Can a patient develop hemoptysis after an ultrasound‑guided thyroid fine‑needle aspiration (FNA)?
In a patient with systemic lupus erythematosus who has low hemoglobin, low mean corpuscular volume, low iron saturation, low total iron‑binding capacity, and ferritin of 91 ng/mL, could this anemia be due to iron deficiency?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.